pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,077 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT806Endpoints606BioPharma Dive231onclive165Fierce Biotech74BioSpace71raps32fda press20globenewswire health
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond
    Dr Nunnery and Annie Bond discuss breast cancer survivorship and patient advocacy.
    onclive · 2mo ago↗ source
  • AUA and SUO Amend Advanced Prostate Cancer Guideline
    The AUA and SUO released the 2026 amendment to the Advanced Prostate Cancer Guideline.
    onclive · 2mo ago↗ source
  • STAT+: Why Marty Makary was the worst FDA commissioner in 25 years
    Marty Makary, who resigned under pressure from the FDA, brought to the job a fundamental lack of understanding of the nature of the role, STAT's Matthew Herper writes.
    STAT · 2mo ago↗ source
← prev
page 32 of 44
next →
20
fda recalls20
fda medwatch16
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • Dr Postow on an Ideal Post-ICI Monitoring Framework in Melanoma
    Michael A. Postow, MD, discusses the importance of long-term multidisciplinary follow-up for patients with melanoma treated with ICIs.
    onclive · 2mo ago↗ source
  • Dr Postow on the Timing of Delayed or Re-Emergent irAEs in Melanoma
    Michael A. Postow, MD, discusses the evolving understanding of ICIs in melanoma and the unique toxicity profiles associated with these agents.
    onclive · 2mo ago↗ source
  • Males who discuss suicide seek help less often than females, report finds
    Out of 1.5 million messages received in 2025, the Crisis Text Line found that less then 20% of the texters identified as male only
    STAT · 2mo ago↗ source
  • STAT+: European Union inks a draft deal to boost local production of medicines and avoid shortages
    The E.U. reached a provisional deal to strengthen the supply of essential medicines and avoid shortages by ‌boosting domestic production and reducing reliance on imports.
    STAT · 2mo ago↗ source
  • STAT+: Makary departs FDA amid turmoil as Diamantas, agency’s top food official, steps in
    Food and Drug Administration Commissioner Marty Makary is resigning from his role after a tumultuous tenure.
    STAT · 2mo ago↗ source
  • Supreme Court extends mifepristone deadline
    The deadliest drug in the country, the new name for PCOS, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
  • STAT+: Hims takes a $33 million hit from GLP-1 ‘pivot’
    In this edition of STAT Health Tech: Hims earnings, Omada's PBM strategy, and the uphill battle faced by new sepsis algorithms.
    STAT · 2mo ago↗ source
  • STAT+: Hims’ sales miss as telehealth competition grows
    Bristol's partnership with Hengrui Pharma, Viiv loses HIV treatment case, and more biotech news from The Readout
    STAT · 2mo ago↗ source
  • Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence Risk
    A Fox Chase Cancer Center study will evaluate a tumor-informed, whole-genome sequencing–based test to assess recurrence risk in early-stage NSCLC.
    onclive · 2mo ago↗ source
  • FDA Grants Breakthrough Therapy Designation to Emi-Le for Adenoid Cystic Carcinoma
    Emi-Le received breakthrough therapy designation from the FDA for the treatment of patients with locally advanced, recurrent or metastatic ACC.
    onclive · 2mo ago↗ source
  • [177Lu]Lu-D-Dan-Phe-PSMA Demonstrates Manageable Safety and Early Efficacy mCRPC
    [177Lu]Lu-D-Dan-Phe-PSMA showed early signals of safety and activity in mCRPC.
    onclive · 2mo ago↗ source
  • FDA Issues Warning Regarding Risk of Secondary Primary Malignancies With Tazemetostat in Follicular Lymphoma, Epithelioid Sarcoma
    The FDA issued a warning about the risk of secondary primary malignancies associated with tazemetostat in epithelioid sarcoma and follicular lymphoma.
    onclive · 2mo ago↗ source
  • STAT+: STAT examines America’s deadliest drug
    STAT examines America's failure to address excessive alcohol use across decades.
    STAT · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more
    The 17 pharmaceutical companies anchoring TrumpRx poured more than $130 million into federal lobbying in 2025 — a nearly 23% surge
    STAT · 2mo ago↗ source
  • GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
    We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.
    onclive · 2mo ago↗ source
  • Unmet Needs in Endometrial Cancer
    Important unmet needs remain in endometrial cancer even as antibody drug conjugates begin to expand the therapeutic armamentarium.
    onclive · 2mo ago↗ source
  • EGFR-Mutated NSCLC: Mechanism and Clinical Role of TROP2-Directed ADCs
    In this segment, Dr. Sands asks the panel to discuss the emerging role of TROP2-directed antibody–drug conjugates in EGFR-mutated non-small cell lung cancer. Dr. Wakelee and Dr. Cooper explain that…
    onclive · 2mo ago↗ source
  • Future Directions in Relapsed and Refractory Multiple Myeloma
    onclive · 2mo ago↗ source
  • Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal Cancer
    Aparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas.
    onclive · 2mo ago↗ source
  • Sequencing Strategies After Progression in Multiple Myeloma
    onclive · 2mo ago↗ source
  • EGFR-Mutated NSCLC: Targeting MET-Driven Resistance in Second-Line Therapy
    In this segment, Dr. Sands asks Dr. Wakelee to discuss how emerging data on MET-driven resistance mechanisms are shaping second-line treatment decisions in EGFR-mutated non-small cell lung cancer.
    onclive · 2mo ago↗ source
  • Sequencing ADCs in Endometrial Cancer
    Sequencing therapy in recurrent endometrial cancer is becoming more complicated as immunotherapy moves earlier and antibody drug conjugates gain momentum.
    onclive · 2mo ago↗ source